Director
Columbia University Medical Center
New York, NY, United States
Academic rheumatologist
Saturday, November 16, 2024
10:30 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose
Sunday, November 17, 2024
5:45 PM – 7:45 PM Eastern Time
No financial relationships with ineligible companies to disclose
Applying the Guidelines to Membraneous Lupus Nephritis
Monday, November 18, 2024
10:45 AM – 11:00 AM Eastern Time
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Consultant (Ongoing); biogen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Idorsia: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Terminated); Sanofi: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)
Monday, November 18, 2024
11:15 AM – 11:30 AM Eastern Time
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Consultant (Ongoing); biogen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Idorsia: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Terminated); Sanofi: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)
Is the Promise of CAR-T Too Good to Be True for Most Patients with Rheumatic Diseases?
Monday, November 18, 2024
1:20 PM – 1:40 PM Eastern Time
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Consultant (Ongoing); biogen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Idorsia: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Terminated); Sanofi: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)
Monday, November 18, 2024
1:40 PM – 2:00 PM Eastern Time
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Consultant (Ongoing); biogen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Idorsia: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Terminated); Sanofi: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)
Evaluating Lupus Arthritis: Novel Imaging Techniques
Monday, November 18, 2024
3:30 PM – 3:50 PM Eastern Time
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Consultant (Ongoing); biogen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Idorsia: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Terminated); Sanofi: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)
19T15: Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Targets, Outcomes & Comorbidity
Tuesday, November 19, 2024
11:00 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose